The SP could easily double based on results of RCT and our MC would still only be around $22M. It also cheep considering our annual revenue is around US$10M with a lot of space to improve in near future. Mr Market is always future looking... The time will tell.
Ann: VTI releases full 1-years results of PROTECT Clinical Trial, page-4
Add to My Watchlist
What is My Watchlist?